Christian Sussebach

Clinical Research Director
Sanofi

Presentation(s):

• LB 01.1 - A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis

  Sunday, July 10, 2022
  2:45 PM – 3:00 PM